José Domingo Pedreira Andrade-rekin lankidetzan egindako argitalpenak (26)

2015

  1. Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

    PLoS ONE, Vol. 10, Núm. 10

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

2013

  1. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B

    AIDS, Vol. 27, Núm. 14, pp. 2219-2224

  2. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

  2. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients

    Retrovirology, Vol. 9

2008

  1. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

2005

  1. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1

    Clinical Infectious Diseases, Vol. 41, Núm. 2, pp. 227-232

  2. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients

    Journal of Medical Virology, Vol. 77, Núm. 1, pp. 23-28

  3. Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain

    Clinical Infectious Diseases, Vol. 41, Núm. 9, pp. 1350-1354

2004

  1. Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations

    Journal of Viral Hepatitis

2003

  1. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

    AIDS, Vol. 17, Núm. 7, pp. 1023-1028

2001

  1. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir

    AIDS, Vol. 15, Núm. 13, pp. 1701-1706

  2. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy

    HIV Clinical Trials, Vol. 2, Núm. 5, pp. 429-437

2000

  1. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain

    AIDS, Vol. 14, Núm. 6, pp. 727-732

1999

  1. Hepatitis C and HTV infection: Biological, clinical, and therapeutic implications

    Journal of Hepatology, Supplement, Vol. 31, Núm. 1, pp. 119-123

1997

  1. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients

    Journal of Infection, Vol. 35, Núm. 3, pp. 225-230

1996

  1. Circulating hepatitis C virus genotypes in Spain. The Hepatitis/HIV Spanish Study Group.

    Vox sanguinis, Vol. 70, Núm. 3, pp. 180-181

  2. Interferon α for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus

    Clinical Infectious Diseases, Vol. 23, Núm. 3, pp. 585-591

  3. TRATAMIENTO DE LA HEPATITIS CRONICA C CON INTERFERON EN PACIENTES INFECTADOS POR EL VIRUS DE LA INMUNODEFICIENCIA HUMANA

    Medicina Clinica, Vol. 106, Núm. 13, pp. 486-490